While the overall effect was weak, it was consistently observed in 39/52 patient samples (median SI: 0.02), suggesting that a part of MEK activation in CLL is independent of the BCR. This evidence concerns the gene MAP2K7 and B-cell chronic lymphocytic leukemia.